Different expression of Micro RNA-126, 133a and 145 in aorta and saphenous vein samples of patients undergoing coronary artery bypass graft surgery

Ahmadreza Jodati1†, Seyed Mohammadbegher Pirouzpanah2,3†, Nazila Fathi Maroufi1,4, Masoud Pezeshkian1, Naser Safaie1, Hossain Bijanpour1, Amir Mahdi Khamaneh4, Ali Mota2, Mohammad Nouri1,2*

1Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2Stem Cell and Regenerative Medicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran
3Evos u1148 Inserm Institut Galilee Universite Paris 13, Paris, France
4Department of Biochemistry & Clinical Laboratory, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
5Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
6Department of Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran

Introduction

Heart failure remains the important trouble to present humanity and treating physician with the most important reason for hospital entrance in adults more than the age of 65. In accordance with World Health Organization (WHO), major factors contributing heart failure are coronary artery disease (CAD), hypertension, diabetes mellitus; atrial fibrillation and valvular heart disease are the five. Micro-RNAs (miRNAs) are highly conserved, non-coding RNA molecules, about 22 nucleotides long, that regulate gene expression on the post-transcriptional level. It is estimated that about one-third of the genes are regulated by miRNAs and a single miRNA can regulate as many as 200 mRNAs. miRNAs act as endogenous repressors of target genes, either by inhibiting translation and/or by promoting degradation of the miRNA, or alternatively by increasing translation. miRNAs have been known to participate in control of most developmental

Abstract

Introduction: microRNAs (miRNAs) are highly conserved, noncoding RNA molecules that regulate gene expression on the post-transcriptional level. Some evidence indicates that microRNAs dysfunction plays a crucial role in human disease development. The role of microRNAs in cardiac growth, hypertrophy, heart failure, cardiovascular complications in diabetes and many other heart conditions are demonstrated. In this study we aimed to evaluate the expression of six microRNAs (mir-100, mir-126, mir-127, mir-133a, mir-133b and mir-145) that have been shown to overexpress in aortic and carotid plaques.

Methods: Thirty Coronary Artery Disease patients who underwent elective coronary artery bypass graft surgery were enrolled in the study. The expression patterns of six miRNAs (mir-100, mir-126, mir-127, mir-133a, mir-133b, and mir-145) were examined in 30 patients of whom we obtained aorta and saphenous vein samples.

Results: In three miRNAs, mir-100, mir-127 and mir-133b, we did not obtain expression data from real-time experiments. We found that the expression level of mir-126, mir-133a and mir-145 were lower in aorta than saphenous vein. Mir-126 was highly expressed in aortic samples (13.8±1.1) when compared with saphenous vein samples (20.2±1.1), although mir-133a was highly expressed in saphenous vein samples (16.1±0.5) when compared with the aorta (17.9±1.5). Expression of mir-145 aortic samples was also dramatically higher than saphenous vein samples (7.2±0.5 versus 10.8±0.6) that was statistically significant (P<0.05).

Conclusion: Understanding the role of miRNAs in cardiovascular physiology and diseases might suggest miRNA-based therapeutic methods in the management of coronary artery disease.
and biological processes ranging from cell cycle control, cell growth and differentiation, apoptosis and so on.\textsuperscript{7} Evidence indicates that miRNAs dysfunction play crucial roles in human disease development.\textsuperscript{7} The role of miRNAs in cardiac growth, hypertrophy, heart failure, cardiovascular complications in diabetes and many other heart conditions are demonstrated.\textsuperscript{8} It is also showed that miRNAs dysfunction may have a critical association with cardiac dysfunction. Different expression of miRNAs in several conditions such as hypertrophy, arrhythmias, atrial fibrillation, heart failure has been studied.\textsuperscript{9,10} Up-regulation of some miRNAs in atherosclerotic plaques have also been shown.\textsuperscript{11,12} The role of miRNAs in vascular smooth muscle cell proliferation, differentiation, and in atherosclerosis has been demonstrated.\textsuperscript{13,14} High levels of miR-1 and miR-133a were shown to be present in acute myocardial infarction (AMI), without increase of serum cardiac troponin or serum creatinine phosphokinase (CPK). As a result, it can be used as a marker of cardiomyocyte damage or death.\textsuperscript{15} Cardiac-specific miRNAs can be used for the recognition of AMI have been describing by a variety of researchers. Cardiac specific miRNAs-1/133/208b/499 may have the potential for future diagnostic markers for AMI.\textsuperscript{15,16} Most studies that have been carried out on their relationship with heart disease have been performed in plasma or serum samples. There are very few studies that have been done on vascular plaques or vascular tissues. On the other hand, all the components involved in heart disease have not yet been fully identified and require further research. Given the discussions in this study we aimed to evaluate the expression of six miRNAs (mir-100, mir-126, mir-127, mir-133a, mir-133b and mir-145) that have been shown to over-expressed in aortic and carotid plaques.\textsuperscript{17,18} For this reason the expression of these microRNAs in aorta and saphenous vein samples obtained during coronary artery bypass surgery and the expression of these miRNAs are assessed.

**Materials and Methods**

**Patients and samples**

Thirty CAD patients who underwent elective coronary artery bypass graft (CABG) surgery enrolled in the study. The study was approved by the local ethics committee of Tabriz University of Medical Sciences. All the patients were clinically symptomatic at presentation and proved to have coronary artery stenosis in angiographic examination. Tiny samples of aorta and saphenous vein (1 to 1.5 g) were taken during the bypass surgery. Samples were rinsed with PBS and were frozen in liquid nitrogen and stored in liquid nitrogen container until RNA extraction.

For all patients, biochemical and laboratory profiles were analyzed in the central laboratory, Shahid Madani Heart Center, using a Hitachi 912 analyzer (Japan). Total serum cholesterol and high density lipoprotein (HDL) cholesterol were measured by an enzymatic colorimetric method, and HDL cholesterol was measured after precipitation with phosphor-tungstate and magnesium ions. Triacylglyceroles were also quantified with an enzymatic colorimetric method. Low-density lipoprotein (LDL) cholesterol was calculated using the Friedewald formula.\textsuperscript{19}

**RNA extraction and cDNA synthesis**

The samples were transferred into RNase free tube and ground. The total RNA was extracted from the samples using mirCURY RNA isolation kit (EXIQON) which intended to extract small RNAs, according to the manufacturer’s instruction. The total RNA concentration was measured using NanoDrop 1000 Spectrophotometer (thermo). RNA samples subjected to DNase I digestion (Thermo Scientific, USA) before cDNA synthesis. One hundred nanograms of total RNA for each sample was reverse-transcribed using mirCURY LNA Universal RT microRNA PCR kit (EXIQON) according to the manufacturer’s instruction. For relative quantification of miRNAs (mir-100, mir-126, mir-127, mir133a, mir-133b, mir-145), PCR amplification kit (mirCURY LNA Universal RT microRNA PCR, EXIQON) with specific primers provided in the kit was used. miR-191 was used as reference gene for data normalization.\textsuperscript{20}

**Statistical analysis**

Statistical analysis was done with SPSS, version 17 (SPSS Inc., USA). Mean values and standard deviations are presented for descriptive. To compare mean values of miRNAs in aorta and saphenous vein samples, paired sample t test was used. To compare mean values of miRNAs in relation to patients BMI independent sample t test was used. Exact P value of <0.05 with 95% confidence interval was considered as statistically significant.

**Results**

**Patient’s characteristics**

Demographic characteristics and laboratory findings for the study group are summarized in Table 1. The majority of patients who underwent CABG surgery were elderly, and male patients are predominant. Based on WHO, BMI classification 14 patients were overweight (BMI, 25.00-29.99) and 11 of them were obese (BMI ≥ 30.00).

**miRNA expression pattern**

The expression patterns of six miRNAs (mir-100, mir-126, mir-127, mir-133a, mir-133b, and mir-145) were examined in 30 patients with CAD from whom we obtained aorta and saphenous vein (Table 2). In three miRNAs, mir-100, mir-127 and mir-133b, we did not obtain expression data from real-time experiments. We found that the expression level of mir-126, mir-133a and mir-145 were lower in aorta in comparison with saphenous vein. These lower expression levels were showed with higher Ct values in real-time quantitative PCR experiments. Mir-126 were essentially highly expressed in saphenous vein samples
Furthermore, recent studies have shown that mir-145 was also different in two groups (10.6±0.6 versus 11.2±0.5) (P<0.05, 95% CI -1.0 to -0.14). It is showed that the expression of mir-133a, however, was not different in two groups (P>0.05, 95% CI -1.2 to 0.4). The expression of miRNAs in the saphenous vein is also shown in Table 3. It showed that the expression of mir-126 in saphenous vein samples in two patients group was not different (P>0.05, 95% CI -0.23 to 1.5). The expression of mir-133a in two patients group was also not different (P>0.05, 95% CI -0.5 to 0.23). The results showed that the expression of mir-145 in the saphenous vein samples of the patients with BMIs lower than 30 was significantly higher than the patients with BMIs upper than 30 (P<0.05, 95% CI -0.8 to -0.03).

**Discussion**

In this study we showed that the expression of mir-126, mir-133a and mir-145 are variably expressed in the aorta and saphenous vein samples from CAD patients. Moreover, we reported that mir-126 is significantly under expressed in aorta samples of overweight patients. Over the past decade several studies have shown abnormal expression pattern of miRNAs in cardiovascular disease such as cardiac hypertrophy, arrhythmias and MI.31,32 There have also shown that many other miRNAs have roles on development of atherosclerosis and play a crucial role in lipoprotein metabolism.32,33 In this study, we found that the expression pattern of mir-126 was different in aorta and saphenous vein samples. Mir-126 was more highly expressed in the saphenous vein. It has shown that mir-126, an endothelial-specific microRNA, regulates many aspects of endothelial cell biology including cell survival and required for governing vascular integrity and maintenance.34 Furthermore, recent studies have shown that mir-126 promotes angiogenic signaling pathways. Fish et al showed that mir-126 is highly expressed in endothelial cells and directly targets Sprouty-related, EVH1 domain-containing protein 1 (SPRED1), vascular cell adhesion protein 1 (VCAM1),

| Variable | Number of diseased vessels | Number of diseased vessels |
|----------|---------------------------|---------------------------|
|          | Aortic stenosis           | Hyperlipidemia            |
|          | Hyper tension             | Diabetes mellitus type 2  |
|          | Aortic stenosis           | Hypertension              |
|          | Total cholesterol (mg/dL) | LDL cholesterol (mg/dL)   |
|          | Triglycerides(mg/dL)      | Fasting blood glucose (mg/dL) |
|          | Na (mg/dL)                | K (mg/dL)                 |
| BMI<30   | (n=19)                    | (n=11)                    |
| BMI>30   | (n=11)                    | (n=11)                    |

Table 3. Expression of miRNAs in aorta and saphenous vein analyzed considering BMIs of the patients

| Variable | BMI<30 (n=19) | BMI>30 (n=11) | P value** |
|----------|--------------|--------------|-----------|
| Aorta    |              |              |           |
| mir-126  | 20.3±0.9**   | 19.6±0.3**   | <0.05     |
| mir-133a | 17.9±1.1**   | 18.3±0.8**   | >0.05     |
| mir-145  | 10.6±0.6**   | 11.2±0.5**   | <0.05     |
| Saphenous|              |              |           |
| mir-126  | 14.3±1.1**   | 13.7±1.1**   | >0.05     |
| mir-133a | 16.1±0.5**   | 16.3±0.5**   | >0.05     |
| mir-145  | 7.1±0.5**    | 7.5±0.3**    | <0.05     |

*Values are obtained by independent sample t test.

**Values are express as Mean± SD

Table 1. Demographic characteristics and laboratory findings

| Variable                      | Number of diseased vessels | Number of diseased vessels |
|-------------------------------|---------------------------|---------------------------|
| Age (y)                       | 60.7±9.6                  |                           |
| Gender (Male/Female)          | 23/7                      |                           |
| BMI (kg/m²)                   | 28.1±3.08                 |                           |
| BMI>30 (n)                    | 11                        |                           |
| Total cholesterol (mg/dL)     | 186±54                    |                           |
| LDL cholesterol (mg/dL)       | 121±44                    |                           |
| HDL cholesterol (mg/dL)       | 38±10                     |                           |
| Triglycerides(mg/dL)          | 156±82                    |                           |
| Fasting blood glucose (mg/dL) | 114±22                    |                           |
| Na (mg/dL)                    | 141.37±0.22               |                           |
| K (mg/dL)                     | 4.38±0.26                 |                           |
| Diabetes mellitus type 2      | 4/30(13.33%)              |                           |
| Hypertension                  | 18/30(60%)                |                           |
| Hyperlipidemia                | 13/30(43.33%)             |                           |
| Aortic stenosis               | 26/30(86.66%)             |                           |
| Number of diseased vessels    |                           |                           |
| One-vessel                    | 7/30(23.33%)              |                           |
| Two-vessel                    | 10/30(33.3%)              |                           |
| Three-vessel                  | 13/30(43.33%)             |                           |

BMi upper than 30 was 19.6±0.3. This expression level was statistically different in two groups (P<0.05, 95% CI 0.06 to 1.2). The results showed that the expression of mir-145 was also different in two groups (10.6±0.6 versus 11.2±0.5) (P<0.05, 95% CI -1.0 to -0.14). It is showed that the expression of mir-133a, however, was not different in two groups (P>0.05, 95% CI -1.2 to 0.4). The expression of miRNAs in the saphenous vein is also shown in Table 3. It showed that the expression of mir-126 in saphenous vein samples in two patients group was not different (P>0.05, 95% CI -0.23 to 1.5). The expression of mir-133a in two patients group was also not different (P>0.05, 95% CI -0.5 to 0.23). The results showed that the expression of mir-145 in the saphenous vein samples of the patients with BMIs lower than 30 was significantly higher than the patients with BMIs upper than 30 (P<0.05, 95% CI -0.8 to -0.03).

Table 2. The expression patterns of six miRNAs (mir-100, mir-126, mir-127, mir-133a, mir-133b, and mir-145)

| miRNA   | Aorta | Saphenous | P value* |
|---------|-------|-----------|----------|
| mir-100 | ND    | ND        |          |
| mir-126 | 20.2±1.1** | 13.8±1.1** | 0.000    |
| mir-127 | ND    | ND        |          |
| mir-133a| 17.9±1.1** | 16.1±0.5** | 0.002    |
| mir-133b| ND    | ND        |          |
| mir-145 | 10.8±0.6** | 7.2±0.5** | 0.000    |

*Values are determine.

**Values are express as mean± SD.

(13.8±1.1) when compared with aorta samples (20.2±1.1) that were statistically significant (P<0.05, 95% CI 1.35 to 2.25). We showed that mir-133a were highly expressed in saphenous vein samples (16.1±0.5) when compared with aorta (17.9±1.5) (P<0.05, 95% CI 5.4 to 7.6). As showed in Table 2, the expression of mir-145 saphenous vein samples was also dramatically higher than aorta (7.2±0.5 versus 10.8±0.6) (P<0.05, 95% CI 3.3 to 3.8). Fold changes of each miR expression were calculated using the 2-DDCt method. The comparative cycle threshold (ΔCt) was defined as a difference between ΔCt (aneurysmal/ normalization) minus ΔCt (nonaneurysmal/normalization).

When the expression of miRNAs in aorta and saphenous vein analyzed considering BMIs of the patients, the results are as followed (Table 3). In this context of patient's BMI, the expressions of mir-126 in aorta samples in patients with BMI lower than 30 was 20.3±0.9 and in patients with

| miRNA   | Aorta | Saphenous | P value* |
|---------|-------|-----------|----------|
| mir-100 | ND    | ND        |          |
| mir-126 | 20.2±1.1** | 13.8±1.1** | 0.000    |
| mir-127 | ND    | ND        |          |
| mir-133a| 17.9±1.1** | 16.1±0.5** | 0.002    |
| mir-133b| ND    | ND        |          |
| mir-145 | 10.8±0.6** | 7.2±0.5** | 0.000    |
and phosphoinositide-3-kinase regulatory subunit 2 (PI3Kδ2) and function to promote vascular endothelial growth factor (VEGF) signaling pathway.\(^{25}\) In addition, it has also shown that VEGF plays a critical role in cardiac angiogenesis following MI.\(^{31}\) Moreover other genes regulated by mir-126 may contribute in responsiveness of endothelial cells to growth factors\(^{26,27}\) and platelet-derived growth factor (PDGF-AB) limits the extent of MI.\(^{27}\) Thus the lower expression of mir-126 in endothelial cells of aorta may involve in development or progression of endothelial dysfunction in CAD patients. In addition to these findings, we found that mir-126 expression in overweight patients even is lower. Despite the higher circulating growth factor levels in patients with higher peri-aortic fat,\(^{28}\) the lower expression of mir-126 may nullify the effect of the growth factor. While the increase in VEGF level may have an angiogenic effect, this may lead to atherosclerosis and plaque instability, a complication that may relate to lower expression of mir-126 in endothelial cells.\(^{26,30}\)

Fichtlscherer et al found that circulating mir-133a was significantly increased in CAD patients. They concluded that mir-133 may be of cardiac muscle origin.\(^{31}\) mir-133a is believed to be specifically expressed in cardiac and muscle tissue and control myogenesis by regulating differentiation process and myoblast proliferation.\(^{32}\) In contrast to these findings, we showed that mir-133a highly expressed in aorta. Mir-133a exerts its critical role in cardiomyocyte proliferation by regulating apoptosis, and it has shown that mir-133a is anti-apoptotic.\(^{33}\)

Izarra et al showed that mir-133a improves the protective capacity of cardiac progenitor cells (CPCs) in MI and exposure to cardiac differentiation progressively increases the expression of miR-133a. These researchers also found that this effect of mir-133a is mediated by preventing apoptosis through caspase 3 inhibition.\(^{34}\) Interestingly, it was shown that the target genes of mir-133a include Bmf (Bcl-2 modifying factor) and Bim (Bcl2l11), which are potent pro-apoptotic factors.\(^{35}\) Remarkably, some miRNAs found to be up-regulated in diseased tissue were down-regulated in the circulation. In current study miR-145 was up-regulated in atria while Fichtlscherer et al showed smooth muscle cell (SMC-derived) miR-145 was down-regulated in the plasma of patients with CAD\(^{36}\); However Cipollone et al demonstrated up-regulation of miR-145 in unstable atherosclerotic plaques.\(^{17}\) Their finding was in accordance with our data. It is potential that diseased tissue specially uptakes exosomes encompassing those specific miRNAs, so lowering their levels in the blood. Other explanations might contain increased deprivation of circulating miRNAs or their epigenetic silencing.\(^{16}\)

**Conclusion**

Improvement and understanding of the role of miRNAs in cardiovascular physiology and diseases, new miRNA-based therapeutic methods are suggested and established in clinical settings and, optimistically, found effective in the treatment of CAD.

**Acknowledgments**

The authors are exceptionally thankful to Tabriz University of Medical Sciences, Tabriz, Iran for financial support and also of all patients who participated in the study. We would also like to thank Dr. Morteza Ghojazadeh for helping us in statistical analyses.

**Ethical approval**

The study protocol was approved by the ethics committee of the Tabriz University of Medical Sciences (ethical code: IR.TBZMED.REC.1395.1219), and informed consent was taken from each case before enrollment.

**Competing interests**

All authors declare no competing financial interests exist.

**References**

1. Maroufi NF, Farzaneh K, Alibabdel M, Zarei L, Cheraghi O, Soltani S, et al. Taq1B Polymorphism of Cholesterol Ester Transfer Protein (CETP) and Its Effects on the Serum Lipid Levels in Metabolic Syndrome Patients. *Biochem Genet* 2016; 54: 894-902. doi: 10.1007/s10528-016-9766-5.

2. Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. *Annu Rev Biochem* 2012; 81: 145-66. doi: 10.1146/annurev-biochem-051410-092902.

3. Keene JD. RNA regulons: coordination of post-transcriptional events. *Nat Rev Genet* 2007; 8: 533. doi: 10.1038/nrg2111.

4. Soheilyfar S, Velashjerdi Z, Hajizadeh YS, Maroufi NF, Amini Z, Khorrarni A, et al. In vivo and in vitro impact of mir-31 and miR-143 on the suppression of metastasis and invasion in breast cancer. *J BUON* 2018; 23: 1290-6.

5. Ha M, Kim VN. Regulation of microRNA biogenesis. *Nat Rev Mol Cell Biol* 2014; 15: 509-24. doi: 10.1038/nrm3838.

6. Krol J, Lodige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. *Nat Rev Genet* 2010; 11: 597. doi: 10.1038/nrg2843.

7. Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease. *Cell* 2012; 148: 1172-87. doi:10.1016/j.cell.2012.02.005.

8. Catalucci D, Gallo P, Condorelli G. MicroRNAs in cardiovascular biology and heart disease. *Circ Cardiovasc Genet* 2009; 2: 402-8. doi: 10.1161/CIRCGENETICS.109.857425.

9. Feng B, Chen S, George B, Feng Q, Chakrabarti S. miR133a regulates cardiomyocyte hypertrophy in diabetes. *Diabetes Metab Res Rev* 2010; 26: 40-9. doi: 10.1002/dmrr.1054.

10. Small EM, Frost RJ, Olson EN. MicroRNAs add a new dimension to cardiovascular disease. *Circulation* 2010; 121: 1022-32. doi: 10.1161/CIRCULATIONAHA.109.889048.

11. Raitoharju E, Oksala N, Lehtimäki T. MicroRNAs in the atherosclerotic plaque. *Clin Chem* 2013; 59: 1708-21. doi: 10.1373/clinchem.2013.204917.

12. Raitoharju E, Lyytikainen LP, Levula M, Oksala N, Mennderand A, Tarkka M, et al. mir-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular Study. *Atherosclerosis*
MicroRNAs in coronary artery disease patients

1. Cordes KR, Sheehy NT, White M, Berry E, Morton SU, Muth AN, et al. miR-145 and miR-143 regulate smooth muscle cell fate decisions. Nature 2009; 460: 705. doi: 10.1038/nature08195.

2. Leeper NJ, Raiesdana A, Kojima Y, Chun HJ, Azuma J, Maegedefessel L, et al. MicroRNA-26a is a novel regulator of vascular smooth muscle cell function. J Cell Physiol 2011; 226: 1035-43. doi: 10.1002/jcp.22422.

3. Kuwabara Y, Ono K, Horie T, Nishi H, Nagao K, Kinoshita M, et al. Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate the existence of myocardial damage. Circ Cardiovasc Genet 2011;4(4):446-54. doi: 10.1161/CIRCGENETICS.111.301209.

4. Matsumoto S, Sakata Y, Suna S, Nakatani D, Usami M, Hara M. Circulating p53-Responsive microRNAs are predictive indicators of heart failure after acute myocardial infarction. Circ Res 2013;113(3):322-6. doi: 10.1161/CIRCRESAHA.113.301209.

5. Sucharov C, Bristow MR, Port JD. miRNA expression in the failing human heart: functional correlates. J Mol Cell Cardiol 2008; 45: 185-92. doi: 10.1016/j.yjmcc.2008.04.014.

6. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.

7. Licholai S, Blaż M, Kapelak B, Sanak M. Unbiased profile of microRNAs after myocardial infarction reveals a role of specific microRNAs miR-1 and miR-133 produced opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes. J Mol Med 2008; 3: 1029-42. doi: 10.1016/j.molmed.2008.03.006.

8. Van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A 2008; 105: 13027-32. doi: 10.1073/pnas.0805038105.

9. Fernández-Hernando C, Suárez Y, Rayner KJ, Moore KJ. MicroRNAs in lipid metabolism. Curr Opin Lipidol 2011; 22: 86. doi: 10.1097/MOL.0b013e328342d9d.

10. Madrigal-Mature J, Roillan N, Aranda JF, Fernández-Hernando C. MicroRNAs and atherosclerosis. Curr Atheroscler Rep 2013; 15: 322. doi: 10.1007/s11883-013-0322-z.

11. Fish JE, Santoro MM, Morton SU, Yu S, Yeh R-F, Wythe JD, et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 2008; 15: 272-84. doi: 10.1016/j.devcel.2008.07.008.

12. Zhao T, Zhao W, Chen Y, Ahokas RA, Sun Y. Vascular endothelial growth factor (VEGF)-A: role on cardiac angiogenesis following myocardial infarction. Microvasc Res 2010; 80: 188-94. doi: 10.1016/j.mvr.2010.03.014.

13. Guo P, Hu B, Gu W, Xu L, Wang D, Huang H-JS, et al. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol 2003; 162: 1083-93. doi: 10.1016/S0002-9440(10)63905-3.

14. Edelberg JM, Lee SH, Kaur M, Tang L, Feirt NM, McCabe S, et al. Platelet-derived growth factor-Aβ limits the extent of myocardial infarction in a rat model. Circulation 2002; 105: 608-13.

15. Kaess BM, Pedley A, Massaro JM, Larson MG, Corsini E, Hoffmann U, et al. Relation of vascular growth factors with CT-derived measures of body fat distribution: the Framingham Heart Study. J Clin Endocrinol Metab 2012; 97: 987-94. doi: 10.1210/jc.2011-2310.

16. Holm PW, Slaat RH, Zeebregts CJ, Hillebrands JL, Tio RA. Atherosclerotic plaque development and instability: a dual role for VEGF. Am J Pathol 2009; 41: 257-64. doi: 10.1080/07853890802516507.

17. Fichtlscherer S, De Rosa S, Fox H, Schwitz T, Fischer A, Liebetrat C, et al. Circulating microRNAs in patients with coronary artery disease: novelty and significance. Circ Res 2010; 107: 677-84. doi: 10.1161/CIRCRESAHA.109.215566.

18. Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 2006; 38: 228-33. doi: 10.1038/ng1725.

19. Xu C, Lu Y, Pan Z, Chu W, Luo X, Lin H, et al. The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes. J Cell Sci 2007; 120: 3045-52. doi: 10.1242/jcs.010728.

20. Izarra A, Moscoso I, Levent A, Cañón S, Cerrada I, Diez-Juan A, et al. miR-133a enhances the protective effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes. J Cell Sci 2007; 120: 3045-52. doi: 10.1242/jcs.010728.